Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis.

Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW.

Clin Infect Dis. 2013 Sep;57(6):828-35. doi: 10.1093/cid/cit411. Epub 2013 Jun 20.

2.

Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.

Saito T, Fujiuchi S, Tao Y, Sasaki Y, Ogawa K, Suzuki K, Tada A, Kuba M, Kato T, Kawabata M, Kurashima A, Sakatani M; NHO Pulmonary Fungosis Research Group.

Infection. 2012 Dec;40(6):661-7. doi: 10.1007/s15010-012-0322-x. Epub 2012 Sep 7.

PMID:
22956473
3.

Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis.

Al-shair K, Atherton GT, Kennedy D, Powell G, Denning DW, Caress A.

Chest. 2013 Aug;144(2):623-31. doi: 10.1378/chest.12-0014.

PMID:
23188518
4.

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.

Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, Cottin V, Jeanfaivre T, Godet C, Pineau M, Germaud P.

Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3231-9. doi: 10.1007/s10096-012-1690-y. Epub 2012 Jul 11.

5.

Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.

Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW.

Clin Infect Dis. 2010 Dec 15;51(12):1383-91. doi: 10.1086/657306. Epub 2010 Nov 5.

6.

The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease.

Lin YX, Xu WN, Liang LR, Pang BS, Nie XH, Zhang J, Wang H, Liu YX, Wang DQ, Xu ZY, Wang HW, Zhang HS, He ZY, Yang T, Wang C.

Chin Med J (Engl). 2009 Dec 20;122(24):2939-44.

PMID:
20137478
7.

Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis.

Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, Koh WJ.

Med Mycol. 2013 Nov;51(8):811-7. doi: 10.3109/13693786.2013.806826. Epub 2013 Jul 9.

PMID:
23834282
8.

Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles.

Koyama K, Ohshima N, Suzuki J, Kawashima M, Takeda K, Ando T, Sato R, Nagai H, Matsui H, Ohta K.

J Infect Chemother. 2014 Jun;20(6):375-9. doi: 10.1016/j.jiac.2014.02.003. Epub 2014 Mar 26.

PMID:
24679654
9.

Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.

Sambatakou H, Dupont B, Lode H, Denning DW.

Am J Med. 2006 Jun;119(6):527.e17-24.

PMID:
16750972
10.

[Short-term efficacy evaluation of chronic pulmonary aspergillosis treated with micafangin and maintenance therapy of itraconazole].

Yasuda S, Ohnishi R, Suzuki T, Sano K, Kato T.

Nihon Kokyuki Gakkai Zasshi. 2009 Nov;47(11):985-90. Japanese.

PMID:
19994592
11.

SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe.

Fležar M, Jahnz-Różyk K, Enache G, Martynenko T, Kristufek P, Škrinjarić-Cincar S, Kadlecová P, Martinovic G.

Int J Chron Obstruct Pulmon Dis. 2013;8:483-92. doi: 10.2147/COPD.S45640. Epub 2013 Oct 9.

12.

Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis.

Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA.

Respir Med. 2008 Nov;102(11):1636-42. doi: 10.1016/j.rmed.2008.05.001. Epub 2008 Aug 8.

13.

Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients.

Kruis AL, van Adrichem J, Erkelens MR, Scheepers H, In 't Veen H, Muris JW, Chavannes NH.

Int J Chron Obstruct Pulmon Dis. 2010 Nov 25;5:407-13. doi: 10.2147/COPD.S9654.

14.

[An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis].

Tomioka H, Kaneda T, Kida Y, Kaneko M, Fujii H, Hayashi M, Tomii K, Tada K, Suzuki Y, Karino T.

Kansenshogaku Zasshi. 2011 Nov;85(6):644-51. Japanese.

PMID:
22250455
15.

Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry.

Camara B, Reymond E, Saint-Raymond C, Roth H, Brenier-Pinchart MP, Pinel C, Cadranel J, Ferretti G, Pelloux H, Pison C; Grenoble Aspergillus Committee.

Clin Respir J. 2015 Jan;9(1):65-73. doi: 10.1111/crj.12105. Epub 2014 Feb 17.

PMID:
24406138
16.

Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

Chishimba L, Niven RM, Cooley J, Denning DW.

J Asthma. 2012 May;49(4):423-33. doi: 10.3109/02770903.2012.662568. Epub 2012 Mar 2.

PMID:
22380765
17.

Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.

Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A.

Mycoses. 2013 Sep;56(5):559-70. doi: 10.1111/myc.12075. Epub 2013 Mar 18. Review.

PMID:
23496375
18.

Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study.

Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K.

Respir Res. 2012 Sep 25;13:85. doi: 10.1186/1465-9921-13-85.

19.

Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis.

Keir GJ, Garfield B, Hansell DM, Loebinger MR, Wilson R, Renzoni EA, Wells AU, Maher TM.

Thorax. 2014 Mar;69(3):287-8. doi: 10.1136/thoraxjnl-2013-203988. Epub 2013 Sep 12.

PMID:
24029745
20.

Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease.

Ferrari R, Tanni SE, Caram LM, Naves CR, Godoy I.

Health Qual Life Outcomes. 2011 Dec 9;9:112. doi: 10.1186/1477-7525-9-112.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk